| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | LNCR2 |
| Entrez GeneID | 1138 |
| clone | 2D2D10 |
| WB Predicted band size | 53kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat |
| Immunogen | Purified recombinant fragment of human CHRNA5 (AA: extra 23-254) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CHRNA5抗体的3篇参考文献示例(注：文献为模拟示例，实际引用请通过学术数据库核实)：
---
1. **标题**: "Development and Validation of a Monoclonal Antibody Specific for the CHRNA5 Nicotinic Receptor Subunit"
**作者**: Johnson, R.B. et al.
**摘要**: 该研究描述了一种针对CHRNA5蛋白胞外结构域的单克隆抗体的开发与验证。通过Western blot和免疫组化验证其特异性，并应用于检测人脑组织及肺癌细胞系中CHRNA5的表达水平，证实其在神经和癌症研究中的实用性。
2. **标题**: "CHRNA5 Expression in Prefrontal Cortex Associates with Nicotine Dependence: An Immunohistochemical Study"
**作者**: Smith, L.M. & Gonzalez, C.
**摘要**: 研究利用CHRNA5抗体对吸烟者与非吸烟者的前额叶皮层样本进行免疫组化分析，发现CHRNA5蛋白表达水平与尼古丁依赖程度显著相关，提示其在成瘾机制中的潜在作用。
3. **标题**: "Epigenetic Regulation of CHRNA5 in Lung Cancer: Insights from Antibody-Based Proteomic Analysis"
**作者**: Chen, X. et al.
**摘要**: 通过结合CHRNA5特异性抗体与质谱技术，该文献揭示了肺癌组织中CHRNA5的表观遗传调控机制，发现其启动子甲基化状态与蛋白表达降低相关，为肺癌治疗提供了新靶点。
---
如需具体文献，建议通过PubMed或Google Scholar以关键词“CHRNA5 antibody”、“CHRNA5 immunohistochemistry”或“CHRNA5 protein expression”检索近期研究。
The CHRNA5 antibody targets the α5 subunit of the neuronal nicotinic acetylcholine receptor (nAChR), encoded by the *CHRNA5* gene. This subunit forms pentameric ligand-gated ion channels, primarily in the central and peripheral nervous systems, mediating synaptic signaling. CHRNA5-containing receptors (e.g., α4β2α5) are implicated in nicotine addiction, cognitive function, and neuropsychiatric disorders. The α5 subunit modulates receptor sensitivity and calcium permeability, influencing neurotransmitter release and synaptic plasticity.
Genetic variations in *CHRNA5*, such as the rs16969968 SNP, are linked to increased nicotine dependence and lung cancer risk, highlighting its clinical relevance. CHRNA5 antibodies are critical tools for studying receptor expression, localization, and function in tissues. They enable techniques like Western blotting, immunohistochemistry, and flow cytometry, aiding research on addiction mechanisms, neurodegenerative diseases (e.g., Alzheimer’s), and cancer biology. In diagnostics, these antibodies may help assess CHRNA5 expression patterns in tumors or neurological conditions. Therapeutic applications are also explored, as modulating α5-containing receptors could offer strategies for smoking cessation or neuroprotection. However, challenges remain in specificity and cross-reactivity due to structural similarities among nAChR subunits. Validated CHRNA5 antibodies are essential for advancing both basic research and translational studies.
×
